http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
고령의 만성 C형 간염 환자에서 Daclatasvir와 Asunaprevir 병용 요법의 유효성 및 안전성 평가
박유경,신수진,최유옥,최혜정,강진숙,황보신이 한국병원약사회 2018 病院藥師會誌 Vol.35 No.4
Background : The prevalence of chronic hepatitis C virus (HCV) tends to be higher in the elderly. Pegylated interferon and ribavirin therapy (Peg-IFN/RBV) was recommended as the first-line treatment in the past decades, but this regimen showed unsatisfactory results in terms of safety and efficacy especially in elderly patients. Recently, it was demonstrated that dual therapy with daclatasvir and asunaprevir was well tolerated and led to high sustained virological response (SVR) rates, irrespective of age. We conducted a study to evaluate the efficacy and safety of daclatasvir plus asunaprevir by involving elderly patients aged above 65 years. Methods : We retrospectively analyzed clinical data from chronic hepatitis C virus (HCV) genotype 1b patients treated with daclatasvir plus asunaprevir from September 2015 to December 2016 at Seoul St. Mary’s hospital. The patients were divided into two groups as elderly patients (older than 65 years) and non-elderly patients (younger than 65 years) and compared the efficacy and safety. Results : A total of 112 patients were treated with daclatasvir plus asunaprevir for chronic hepatitis C. Among them, 101 patients completed the whole treatment, and in 88 patients the amount of HCV RNA was measured after 12 weeks of treatment. There was no significant difference in SVR at 12 weeks between both the groups (p=0.68). Typically, 91.4%(32/35) of elderly patients and 94.3%(50/53) of nonelderly patients achieved SVR12. Common adverse events included elevation in transaminase level, headache, and gastrointestinal disorders. There was no statistical difference in the symptoms between the two groups. Conclusions : The combination therapy with daclatasvir plus asunaprevir exhibited similar rates of SVR12 in HCV elderly patients without leading to further adverse events compared to non-elderly patients. Therefore, it is proposed that daclatasvir plus asunaprevir therapy could be considered as an effective and safe treatment, even in patients aged over 65 years.
신준규(Jun Gyu Shin),강상운(Sang Woon Gang),최유옥(Yoo Ok Choi),정혜인(Hye In Jeong),김경한(Kyeong Han Kim),김홍준(Hong Jun Kim) 대한스포츠한의학회 2021 대한스포츠한의학회지 Vol.21 No.1
Objectives The purpose of this study is to report a clinical case of psoriasis treated with Korean medicine treatment including Yukmijihwangtang-hap-Guibitang-Gagambang, Acupuncture and phototherapy. Methods The severity of psoriasis and pruritus was evaluated with PASI score and VAS respectively during the treatment with Yukmijihwangtang-hap-Guibitang-Gagambang, Saam Acupuncture and infrared-phototherapy. The patient had the treatment total 12 times during 62 days from 18 March 2020 to 18 May 2020. Results After the treatment, PASI score decreased from 10.4 to 1.3 meeting PASI 75 with 87.5% improvement and the patient recorded VAS 0. After the last treatment on 18 May 2020, a follow-up was conducted and found psoriasis had not relapsed. Also the lesion and pruritus had completely been disappeared until 28 July 2021. Conclusions The results indicate that Korean Medicine Treatment can be a practical option for the treatment of psoriasis.